Company intelligence / Profile preview

Espero BioPharma

Jacksonville Beach, Florida, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Tecarfarin is in pivotal Phase 3 trials for oral anticoagulation, leveraging SPA with the FDA for accelerated regulatory pathway. Budiodarone is in Phase 2 for refractory atrial fibrillation, showing improved safety and pharmacokinetics compared to amiodarone. Marketed products include GoNitro (nitroglycerin sublingual powder), Nitrolingual Pumpspray (nitroglycerin spray), and Durlaza (extended-release aspirin), all used for various cardiac indications

Therapeutic areas: HematologyCardiovascular
Modalities: Small moleculeSynthetic vitamin K antagonist (tecarfarin)Antiarrhythmic small molecule (budiodarone)
Industry: Biotech

Partnerships

Merger with ArmetheonPartners: DDB Health and Alamo Pharma Services for GoNitro launch

Beyond the preview

Go deeper on Espero BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Espero BioPharma.

Explore the full profile